• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of applied laboratory medicine. >Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response
【24h】

Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response

机译：评价三个Anti-SARS-CoV-2血清学的免疫测定Post-Vaccine响应

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: In North America, both messenger RNA (mRNA) vaccines, Pfizer-BioNTech BNT162b2, and Moderna mRNA-1273, each utilizing a 2-dose regimen, have started to be administered to individuals. Methods: We evaluated the quantitative serologic antibody response following administration of either a single dose or both doses of an mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in a cohort of 98 participants (88 healthcare workers [HCW] and 10 solid organ transplant [SOT] recipients). Antibody levels were compared across 3 immunoassays: Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics), SARS-CoV-2 TrimericS IgG (DiaSorin), and SARS-CoV-2 IgG II Quant (Abbott). Results: Among HCW, sensitivity ranged from 100% (Roche), 99% (Abbott) and 98% (DiaSorin). The SARS-CoV-2 IgG II Quant and SARS-CoV-2 TrimericS IgG assays showed good agreement with a Pearson correlation coefficient of R = 0.95. Pearson correlation coefficients of R = 0.82 and 0.83 were obtained for Elecsys Anti-SARS-CoV-2 S vs SARS-CoV-2 TrimericS IgG and SARS-CoV-2 IgG II Quant vs Elecsys Anti-SARS-CoV-2 S, respectively. Significant differences in antibody levels between HCW and SOT recipients were observed. A decrease in antibody levels from time of vaccine administration to blood draw was evident. Among those with a second dose, an increase in antibody levels with increased time between administration of the first and second dose was observed. Conclusions: The absolute values generated from each of the assay platforms are not interchangeable. Antibody levels differed with increased time between vaccine administration and with increased time between administration of the first and second dose. Further, significant differences in antibody levels between HCW and SOT recipients were observed.
机译：背景:在北美,信使RNA(mRNA)疫苗,Pfizer-BioNTech BNT162b2,现代化信使rna - 1273,每一个都利用服用方案,开始进行管理个人。定量血清学抗体反应管理一个单剂量或两个剂量的信使rna严重急性呼吸系统综合症冠状病毒2 (SARS-CoV-2)疫苗的98名参与者(88卫生保健工作者(HCW)和10个实体器官移植[说]接受者)。3分析:Elecsys Anti-SARS-CoV-2年代(罗氏诊断),SARS-CoV-2三聚物的免疫球蛋白结果:在HCW,灵敏度范围从100%(罗氏),99% (Abbott)和98% (DiaSorin)。免疫球蛋白皮尔逊化验显示良好的协议的相关系数R = 0.95。相关系数R = 0.82和0.83均获得Elecsys Anti-SARS-CoV-2 vsSARS-CoV-2三聚物的免疫球蛋白和SARS-CoV-2免疫球蛋白II分别定量vs Elecsys Anti-SARS-CoV-2年代。在抗体水平显著差异HCW和受者之间被观察到。从疫苗的抗体水平下降政府抽血是显而易见的。那些拥有第二个剂量,增加抗体水平与政府之间的时间第一次和第二次的剂量观察。结论:从生成的绝对值每一个试验平台可互换的。提高时间管理和疫苗与时间管理之间第一次和第二次剂量。HCW和抗体水平的差异观察移植受者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号